Review sharpens focus on blue-eyed cats, PAX3, and hearing risk

A newly published review, Blue eyes in Felis catus: genetics and health impacts, brings fresh attention to a trait many pet parents and breeders find visually appealing, but that can carry meaningful health implications in some cats. The paper focuses on the genetics behind blue eyes in domestic cats and centers on the dominant blue eye (DBE) phenotype associated with PAX3 variants, especially in cats that otherwise have colored coats. The authors frame the issue as both a genetics story and a welfare story: blue eyes may be marketable, but the underlying biology can overlap with pathways involved in inner ear development and hearing. (link.springer.com)

That distinction matters because not all blue-eyed cats are biologically alike. The review separates three broad mechanisms: KIT-associated dominant white cats, which have a well-established deafness risk; TYR-associated colorpoint cats such as Siamese and Ragdolls, whose blue eyes are not linked to deafness in the same way; and PAX3-associated DBE cats, where blue eyes appear on a colored coat and may be accompanied by white spotting and sensorineural hearing loss. The authors note that breeder selection for unusual aesthetics has helped spread DBE in some lines, particularly as the look has gained popularity in pedigreed cats. (link.springer.com)

The review synthesizes a rapidly growing body of research around four named DBE variants: DBE^CEL, DBE^RE, DBE^ALT, and DBE^AGO. Earlier studies identified different founding effects behind these traits, rather than a single universal mutation. One 2024 study in Maine Coons tied the DBE^RE allele to a heterozygous nonsense variant in PAX3 and documented blue eyes, minimal white spotting, and variable hearing impairment in affected cats. That work used BAER testing to characterize auditory function and reported both unilateral and bilateral sensorineural deafness in some cats, while also showing that not every cat with the variant had the same phenotype. A separate 2025 study described a new PAX3 variant in Maine Coons and added to the evidence that expression can be variable, including so-called latent carriers in at least one lineage. (pubmed.ncbi.nlm.nih.gov)

The biology behind the concern is plausible and familiar to veterinary genetics: melanocyte development affects both pigmentation and normal cochlear function. In the review, the authors explain that disruption of melanocyte migration, survival, or differentiation can impair the stria vascularis and contribute to cochlear degeneration, helping explain why some pigmentation phenotypes track with deafness risk. That mechanism is well established in white cats, and the newer DBE literature suggests some PAX3-driven blue-eye phenotypes may fit into a related auditory-pigmentary framework. The Maine Coon study explicitly compared the presentation to a Waardenburg syndrome-like picture in humans. (link.springer.com)

Outside the paper itself, breeder organizations and registry stakeholders are already reacting. A FIFe health and welfare document described DBE as an increasingly popular trait, especially in Maine Coons, and said the Maine Coon Breed Council recommends against using DBE cats in breeding programs while encouraging PAX3 testing to identify risks such as deafness and Waardenburg syndrome-like changes. TICA materials reviewed online also summarize the known PAX3-linked DBE mutations as being associated with deafness, and one 2026 committee appendix went further, recommending that DBE carriers be discouraged from intentional breeding because of links to deafness, developmental problems, and welfare concerns. These statements are not peer-reviewed clinical guidance, but they do show how quickly the conversation has moved from novelty trait to risk management. (fifeweb.org)

Why it matters: For veterinary professionals, this review is most useful as a framework for counseling. A blue-eyed cat with a colored coat should not automatically be treated as equivalent to a Siamese-pattern cat, nor should appearance alone be used to estimate hearing risk. The paper supports a more precise conversation around phenotype, pedigree, and available testing. In practice, that means considering BAER testing when hearing status is uncertain, discussing genetic testing where relevant, and helping pet parents understand that a sought-after appearance may reflect different underlying mechanisms with different welfare implications. It also underscores the importance of careful language: the risk signal appears strongest in specific DBE lineages, not in every blue-eyed cat. (link.springer.com)

There’s also a broader clinical-research takeaway. The review argues that modern molecular tools now make it harder to justify breeding strategies that prioritize appearance first and sort out health consequences later. That’s especially relevant in cats, where small founder populations can rapidly concentrate both desired traits and unintended disease risk. For veterinarians working with breeders, rescue groups, or pet parents adopting pedigreed kittens, the paper offers a timely evidence base for discussing screening, informed breeding choices, and realistic expectations about hearing outcomes. (link.springer.com)

What to watch: The next phase will likely be more genotype-phenotype work across breeds, better prevalence estimates for deafness within each DBE lineage, and possible refinement of registry rules around testing and registration of blue-eyed, colored-coat cats. FIFe board materials published in 2026 suggest those policy questions are already active, particularly in Maine Coons. (fifeweb.org)